** U.S.-listed shares of Australia-based Mesoblast MSB.AX rise 44.2% to $17.67 premarket
** The U.S. Food and Drug Administration late on Wednesday approved co's cell therapy for treating graft-versus-host disease (GVHD)
** The therapy, branded as Ryoncil, is approved to treat pediatric patients aged two months and older whose GVHD symptoms have not responded to standard steroid therapy
** GVHD is a complication that might occur after a cell transplant, where the donated stem cells attack the recipient's cells, mistaking them for an unfamiliar threat
** Up to last close, stock rose ~457% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.